Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Activating signal cointegrator 1 (TRIP4) is a transcriptional coactivator protein encoded by the TRIP4 gene and functions as a subunit of the tetrameric ASC-1 nuclear complex. TRIP4 interacts with ligand-bound nuclear receptors—including thyroid hormone receptor and retinoid X receptor alpha—to facilitate receptor-mediated transcription in the nucleus. It binds transcriptional coactivators such as EP300, CREBBP, and Nuclear receptor coactivator 1, and also modulates estrogen and androgen receptor activities. TRIP4 participates in the ribosome quality control pathway and is important for neuromuscular and myogenic differentiation. Disease relevance includes its role in spinal muscular atrophy with congenital bone fractures and certain cancers through MAPK, PI3K/AKT, and hTERT signaling activation.
Drugs targeting nuclear hormone receptors (e.g., thyroid hormone receptor modulators) may depend on TRIP4-mediated coactivation for transcriptional effects
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Activating signal cointegrator 1 (TRIP4).